Cue Biopharma (CUE) Appoints Lucinda Warren as Interim President and CEO [Yahoo! Finance]
Cue Biopharma, Inc. (CUE)
US:NASDAQ Investor Relations:
cuebiopharma.gcs-web.com/news-releases
Company Research
Source: Yahoo! Finance
Cue Biopharma Inc. (NASDAQ: CUE ) is one of the unstoppable stocks that could double your money. On March 27, Cue Biopharma announced a leadership transition, appointing Lucinda Warren as interim president and chief executive officer. Warren, who joined the company in 2024 and most recently served as chief financial & business officer, succeeds Usman Azam. Dr. Azam stepped down from his executive roles and the board of directors as of March 26. Warren brings over 30 years of global pharmaceutical and biotechnology experience to the position, including a significant tenure at Johnson & Johnson, where she led business development for neuroscience and the Japan region. During her time at Cue Biopharma, she has been instrumental in executing several high-value strategic transactions. These include the return of worldwide rights for CUE-401, a collaboration with Boehringer Ingelheim for CUE-501, and a license agreement with ImmunoScape for solid tumor cell therapies. Cue Biopharma (CU
Show less
Read more
Impact Snapshot
Event Time:
CUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CUE alerts
High impacting Cue Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
CUE
News
- Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026GlobeNewswire
- Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License AgreementGlobeNewswire
- Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases Transcript [Seeking Alpha]Seeking Alpha
- Cue Biopharma Announces CEO Transition [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma Announces CEO Transition [TheStreet.com]TheStreet.com
CUE
Sec Filings
- 4/13/26 - Form 8-K
- 4/10/26 - Form 4
- 4/10/26 - Form 4
- CUE's page on the SEC website